{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T15:22:07Z","timestamp":1762183327974,"version":"build-2065373602"},"reference-count":37,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2010,9,14]],"date-time":"2010-09-14T00:00:00Z","timestamp":1284422400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J American Geriatrics Society"],"published-print":{"date-parts":[[2010,10]]},"abstract":"<jats:p>\n                    <jats:bold>OBJECTIVES:<\/jats:bold>\n                    To determine the effect of colony\u2010stimulating factor (CSF) on incidence of febrile neutropenia, infection, and survival in older people with non\u2010Hodgkin's lymphoma (NHL) treated with chemotherapy.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>DESIGN:<\/jats:bold>\n                    Retrospective cohort study.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>SETTING:<\/jats:bold>\n                    The Surveillance, Epidemiology, and End Results\u2013Medicare database.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>PARTICIPANTS:<\/jats:bold>\n                    Thirteen thousand two hundred twenty\u2010three people diagnosed with NHL at age 65 and older (mean age 74.9, range 65\u2013102) in 1992 to 2002 who received chemotherapy within 12 months of diagnosis.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>MEASUREMENTS:<\/jats:bold>\n                    Primary prophylaxis was defined as CSF administered at the start of chemotherapy before febrile neutropenia or infection; secondary prophylaxis was defined as CSF use after febrile neutropenia or infection.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>RESULTS:<\/jats:bold>\n                    Participants with five to nine administrations of primary prophylactic CSF had a 42% lower risk of febrile neutropenia (odds ratio (OR)=0.58, 95% confidence interval (CI)=0.41\u20130.83), and participants with 10 or more administrations had a 48% lower risk (OR=0.52, 95% CI=0.36\u20130.76) after adjusting for age, stage, histology, and comorbidity. Results did not differ significantly after adjusting for propensity score of receiving CSF. There was no significant association between primary prophylactic CSF and overall survival, but secondary prophylactic CSF was significantly associated with better survival. Four to 10 administrations of secondary prophylactic CSF was associated with 9% lower mortality risk (hazard ratio (HR)=0.91, 95% CI=0.84\u20130.99), 11 to 23 administrations was associated with 23% lower mortality risk (HR=0.77, 95% CI=0.71\u20130.84) and 24 or more administrations was associated with 13% lower mortality risk (HR=0.87, 95% CI+0.79\u20130.95) than in participants not receiving CSF after neutropenia or infection.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>CONCLUSION:<\/jats:bold>\n                    Primary prophylactic CSF was observed to be effective in reducing the incidence of neutropenia and infection. These findings substantiate the clinical guidelines for recommending prophylactic CSF in older people with NHL receiving chemotherapy.\n                  <\/jats:p>","DOI":"10.1111\/j.1532-5415.2010.03081.x","type":"journal-article","created":{"date-parts":[[2010,9,14]],"date-time":"2010-09-14T13:21:59Z","timestamp":1284470519000},"page":"1885-1895","source":"Crossref","is-referenced-by-count":19,"title":["Comparative Effectiveness of White Blood Cell Growth Factors on Neutropenia, Infection, and Survival in Older People with Non\u2010Hodgkin's Lymphoma Treated with Chemotherapy"],"prefix":"10.1111","volume":"58","author":[{"given":"Stephen K.","family":"Gruschkus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Lairson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Kay","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Risser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianglin L.","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,9,14]]},"reference":[{"key":"e_1_2_6_2_2","unstructured":"American Cancer Society Cancer Facts and Figures 2008 [on\u2010line]. Available athttp:\/\/www.cancer.orgAccessed December 21 2008."},{"key":"e_1_2_6_3_2","unstructured":"National Cancer Institute.Surveillance Epidemiology and End Results (SEER) Cancer Statistics Review 1975\u20132004 [on\u2010line]. Available athttp:\/\/seer.cancer.gov\/csr\/1975_2004\/sections.htmlAccessed December 21 2008."},{"key":"e_1_2_6_4_2","first-page":"2352","article-title":"Elderly patients with aggressive non\u2010Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte\u2010macrophage colony\u2010stimulating factor","volume":"16","author":"Gomez H","year":"1998","journal-title":"Identification of two age subgroups with differing hematologic toxicity"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00062752-200205000-00006"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(02)00730-1"},{"key":"e_1_2_6_7_2","first-page":"66","article-title":"Suboptimal dosing in adjuvant breast cancer chemotherapy","volume":"64","author":"Crawford J","year":"2000","journal-title":"Evidence from a nationwide survey"},{"key":"e_1_2_6_8_2","first-page":"394A","article-title":"Clinical prediction models for febrile neutropenia and relative dose intensity in patients receiving adjuvant breast cancer chemotherapy","volume":"20","author":"Lyman GH","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_6_9_2","first-page":"5","volume-title":"Filgrastim (r\u2010metHuG\u2010CSF in Clinical Practice. 2","author":"Roskos LK","year":"1998"},{"key":"e_1_2_6_10_2","first-page":"5155","article-title":"Human hematopoietic growth factors","volume":"20","author":"Dempke W","year":"2000","journal-title":"Old lessons and new perspectives"},{"key":"e_1_2_6_11_2","first-page":"4198","article-title":"C olony\u2010stimulating factors for chemotherapy\u2010induced febrile neutropenia","volume":"23","author":"Clark OA","year":"2005","journal-title":"A meta-analysis of randomized controlled trials"},{"key":"e_1_2_6_12_2","first-page":"3158","article-title":"Impact of primary prophylaxis with granulocyte colony\u2010stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy","volume":"25","author":"Kuderer NM","year":"2007","journal-title":"A systematic review"},{"key":"e_1_2_6_13_2","doi-asserted-by":"crossref","unstructured":"BohliusJ HerbstC ReiserMet al. Granulopoiesis\u2010stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev 2008;(4):CD003189.","DOI":"10.1002\/14651858.CD003189.pub4"},{"key":"e_1_2_6_14_2","first-page":"3187","article-title":"2006 update of recommendations for the use of white blood cell growth factors","volume":"24","author":"Smith TJ","year":"2006","journal-title":"An evidence-based clinical practice guideline"},{"issue":"8","key":"e_1_2_6_15_2","first-page":"IV\u20103\u201018","article-title":"Overview of the SEER\u2010Medicare data","volume":"40","author":"Warren JL","year":"2002","journal-title":"Content, research applications, and generalizability to the United States elderly population"},{"key":"e_1_2_6_16_2","first-page":"8620","article-title":"Temporal and geographic variation in the use of hematopoietic growth factors in older women receiving breast cancer chemotherapy","volume":"23","author":"Du XL","year":"2005","journal-title":"Findings from a large population-based cohort"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2007.03.011"},{"key":"e_1_2_6_18_2","first-page":"823","article-title":"Verifying assumptions of the proportional hazards model","volume":"11","author":"Harrell F","year":"1986","journal-title":"Proc 11th Annual SAS User's Group Int"},{"key":"e_1_2_6_19_2","first-page":"630","article-title":"Changes in cancer registry coding for lymphoma subtypes","volume":"15","author":"Clarke CA","year":"2006","journal-title":"Reliability over time and relevance for surveillance and study"},{"key":"e_1_2_6_20_2","first-page":"413","article-title":"Impact of granulocyte colony\u2010stimulating factor (CSF) and granulocyte\u2010macrophage CSF in patients with malignant lymphoma","volume":"122","author":"Bohlius J","year":"2003","journal-title":"A systematic review"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(03)00662-2"},{"issue":"2","key":"e_1_2_6_22_2","first-page":"28","article-title":"Prophylactic granulocyte colony\u2010stimulating factor (G\u2010CSF) added to CHOP in the treatment of elderly patients with aggressive non\u2010Hodgkin's lymphoma (NHL). Final results of a multicenter phase 3 study","volume":"13","author":"Doorduijn JK","year":"2002","journal-title":"Ann Oncol"},{"key":"e_1_2_6_23_2","first-page":"963","article-title":"Prognostic significance of actual dose intensity in diffuse large\u2010cell lymphoma","volume":"8","author":"Kwak LW","year":"1990","journal-title":"Results of a tree-structured survival analysis"},{"key":"e_1_2_6_24_2","first-page":"651","article-title":"Prognostic significance of received relative dose intensity in non\u2010Hodgkin's lymphoma patients","volume":"4","author":"Lepage E","year":"1993","journal-title":"Application to the LNH-87 protocol. The GELA (Groupe d'Etude des Lymphomas de l'Adult)"},{"key":"e_1_2_6_25_2","first-page":"599","article-title":"Randomized trial of rmetHu granulocyte colony\u2010stimulating factor (G\u2010CSF) as adjunct to CHOP or CNOP treatment of elderly patients with aggressive non\u2010Hodgkin's lymphoma","volume":"95","author":"Bjorkholm M","year":"1999","journal-title":"Blood"},{"key":"e_1_2_6_26_2","first-page":"3974","article-title":"Randomized trial with or without granulocyte colony\u2010stimulating factor as adjunct to induction VNCOP\u2010B treatment of elderly high\u2010grade non\u2010Hodgkin's lymphoma","volume":"89","author":"Zinzani PL","year":"1997","journal-title":"Blood"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199107183250305"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djk028"},{"key":"e_1_2_6_29_2","first-page":"3871","article-title":"Acute myeloid leukemia after adjuvant breast cancer therapy in older women","volume":"25","author":"Patt DA","year":"2007","journal-title":"Understanding risk"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1988.00380100106022"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19941001)74:7 <2208::AID-CNCR2820741737>3.0.CO;2-#"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199912303412706"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.08.010"},{"key":"e_1_2_6_34_2","first-page":"2720","article-title":"Participation in cancer clinical trials","volume":"291","author":"Murthy VH","year":"2004","journal-title":"Race-, sex-, and age-based disparities"},{"key":"e_1_2_6_35_2","first-page":"1455","article-title":"Patterns of use of chemotherapy for breast cancer in older women","volume":"19","author":"Du XL","year":"2001","journal-title":"Findings from Medicare claims data"},{"key":"e_1_2_6_36_2","doi-asserted-by":"crossref","first-page":"IV\u201055\u201061","DOI":"10.1097\/00005650-200208001-00008","article-title":"Utility of the SEER\u2010Medicare data to identify chemotherapy use","volume":"40","author":"Warren JL","year":"2002","journal-title":"Med Care"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji189"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000196978.34283.a6"}],"container-title":["Journal of the American Geriatrics Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1532-5415.2010.03081.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/agsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1532-5415.2010.03081.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T14:31:14Z","timestamp":1762180274000},"score":1,"resource":{"primary":{"URL":"https:\/\/agsjournals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1532-5415.2010.03081.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,14]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["10.1111\/j.1532-5415.2010.03081.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1532-5415.2010.03081.x","archive":["Portico"],"relation":{},"ISSN":["0002-8614","1532-5415"],"issn-type":[{"type":"print","value":"0002-8614"},{"type":"electronic","value":"1532-5415"}],"subject":[],"published":{"date-parts":[[2010,9,14]]}}}